The global companion diagnostic tests in oncology market is anticipated to witness moderate to high growth as numerous market players are collaborating with pharmaceutical manufacturers, reports Transparency Market Research (TMR). Additionally, there is a rise in number of new entrants in the market, thereby putting the position of prominent players at risk. Prominent players in the companion diagnostic tests in oncology market include Illumina Inc., and Agilent Technologies Inc. These companies emphasize on new product developments and account for a substantial share in the global companion diagnostic tests in oncology market market.
As per expert analysts, the global companion diagnostic tests in oncology market is anticipated to garner a stellar CAGR of 16.8%. during the forecast period which is 2017 to 2025. Growing at this pace, the market is expected to reach a valuation of US$13.6 by the end of the forecast period.
Based on biomarker, the global companion diagnostic tests in oncology market is categorized into EGFR, KRAS, HER2, BRAF V600E, and others. Out of these, the EFGR segment has registered the highest growth and is expected to withhold its position throughout the forecast period. This is on account of factors search as rising prevalence of lung cancer and increase in research and development activities.
On the regional front, the global companion diagnostic tests in oncology market is classified into Asia-Pacific, Europe, Latin America, Middle East and Africa, and North America. Out of these, North America dominates the market and is perceived to hold a 37.5% of the market’s share by the end of the forecast period.
Rising Prevalence of Cancer to Boost Growth
Due to advancements in healthcare facilities and rising awareness, there has been a surge in demand for advanced therapies and personalized medicines. This is a key factor driving the growth of the global companion diagnostic tests in oncology market. Additionally, rising prevalence of cancer and high investment in its treatment have led to a spur in demand for advanced therapies for cancer treatment, thereby expediting the companion diagnostic tests in oncology market’s growth.
In addition to the aforementioned drivers, an unhealthy lifestyle and increased smoking leading to lung cancer have stimulated the market’s expansion. Moreover, new technological developments and rising research activities pertaining to medical diagnostic devices have resulted in a great adoption of diagnostic tests. This has impacted the companion diagnostic tests in oncology market positively, thereby stirring its growth.
However, there are a few restraints that may cause a downfall in the companion diagnostic tests in oncology market. Complications related to reimbursement and delay in the approvals may dissuade the market’s growth. Nonetheless, rise in funding from governments and numerous cancer welfare organizations may reduce the effects of the restraints. Additionally, recent developments in the pharmaceutical and biotechnology industry may attract consumers to the companion diagnostic tests in oncology market, thereby benefitting its growth.
Strategic Collaborations to Present New Opportunities for the Market
Key manufacturers of the diagnostic devices are increasingly collaborating with prominent pharmaceutical companies for the development of new devices and solutions that offer better results. For instance, NanoString Technologies collaborated with Astellas and Medivation to enhance PAM50-based Prosigna Breast Cancer Assay. Such collaborations have resulted in the development of enhanced solutions, thereby creating new avenues for the global companion diagnostic tests in oncology market. In addition, reduction in the drug discovery cost has also presented new growth opportunities for the market.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Companion Diagnostic Tests in Oncology Market (Detection Technique - Protein Detection, DNA Detection (Polymerase Chain Reaction, Next Generation Sequencing, and In Situ Hybridization (Fluorescence In Situ Hybridization, and Chromogenic In Situ Hybridization)); Biomarker - EGFR, BRAF V600E, KRAS, and HER2; Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, and Melanoma; End User - Pharmaceutical and Biotechnology Companies, Medical Device Companies, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.”
The global companion diagnostic tests in oncology market is segmented based on:
- Detection Technique
- Protein Detection
- DNA Detection
- Polymerase Chain Reaction (PCR)
- Next Gen Sequencing (NGS)
- In Situ Hybridization
- Fluorescence In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
- BRAF V600E
- Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Liver Cancer
- End Users
- Pharmaceutical & Biotechnology Companies
- Medical Device Companies
- Research Institutes
- North America
- Latin America
- Middle East & Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
7 of 10 large enterprizes view our Report to take the right decision.View Report